ESMO 2024
New updates from the innovative I-SPY program
I-SPY 2.2, I-SPY 2.2
ESMO 2024
New updates from the innovative I-SPY program
WSG-TP-II, HERA, NATALEE, ShortHER
ESMO 2024
Therapy de-escalation and balancing individualized…
NATALEE
ESMO 2024
4-year update of Riboclib in EBC - can we avoid chemo?
KEYNOTE 522, TNBC-DX, PROMENADE
ESMO 2024
Escalation, De-escalation and management of therapy:…
UNICANCER
ESMO 2024
Hypofractionation in early breast cancer
KEYNOTE-522
ESMO 2024
Survival benefit reported with Pembro
WSG-TP-II
ESMO 2024
Survival data from WSG-TP-II
OptiTrain
ESMO 2024
Physical exercise and oncological outcome
KEYNOTE-522
ESMO 2024
Overall survival advantage for Pembrolizumab in early…
ESMO 2024
Registry data from France - no break in endocrine…
ESMO 2024
Compliance is everything
HERA
ESMO 2024
Endocrine therapy in triple-positive premenopausal…
NATALEE
ESMO 2024
Evaluation of the patient collective under 40 years
NATALEE
ESMO 2024
4-year landmark data
NATALEE
ESMO 2024
Ribociclib in younger patients
NATALEE
ESMO 2024
Update on NATALEE in young patients
NATALEE
ESMO 2024
Update on NATALEE in young patients
OptiTrain
ESMO 2024
Physical exercise and oncological outcome
DETECT-V, ABIGAIL
ESMO 2024
De-Escalation in the metastatic setting
DESTINY-Breast06
ESMO 2024
T-DXD for everyone - what is the minimal threshold for…
shortHER
ESMO 2024
TILs and overall survival in the shortHER trial
ESMO 2024
Brain imaging screening in MBC patients
CAPItello290
ESMO 2024
No benefit of Akt-inhibition in mTNBC
KEYNOTE-522, NATALEE, ICARUS-Breast-01, DESTINY-Breast 12
ESMO 2024
Highlights of ESMO 2024
eMouvoir, OPTItrain
ESMO 2024
Keep the patients trained!
CAPItello-290
ESMO 2024
PIK3CA is not a vaild pathway in triple-negative breast…
CAPItello-290
ESMO 2024
Akt-inhibition works with HR+ but not with mTNBC
ESMO 2024
Brain imaging screening in MBC patients
ESMO 2024
New approaches to treat 1L patients mTNBC
shortHER
ESMO 2024
TILs e sopravvivenza nello studio shortHER
CAPItello-290
ESMO 2024
PIK3CA is not a vaild pathway in triple-negative breast…
KEYNOTE-522, NATALEE, ICARUS-Breast-01, DESTINY-Breast 12
ESMO 2024
Punti salienti di ESMO 2024
ESMO 2024
Nuovi approcci per il trattamento dei pazienti 1L mTNBC
ICARUS-Breast-01, CAPItello290
ESMO 2024
Promosing results for the new ADC in HR+ - negative…
DESTINY-Breast 12
ESMO 2024
New first choice treatment for patients with brain…
ESMO 2024
ctDNA data and clinical efficacy of SG
DETECT V
ESMO 2024
Soon no chemotherapy for triplenegative mBC
DestinyBreast-012
ESMO 2024
T-Dxd in patients with and without brain metastases
ICARUS-Breast-01
ESMO 2024
Study impression in HR+/HER2- mBC progressing after two…
DESTINY-Breast12
ESMO 2024
Efficacy of T-Dxd in patients with brain metastasis
DESTINY-Breast 12
ESMO 2024
T-Dxd in BrainMets
DestinyBreast-012
ESMO 2024
Primary systematic treatment of active brain metastases
DETECT V
ESMO 2024
Endocrine-based therapy in combination with dual…
ESMO 2024
High sensitivity testing as outcome predictor for T-DXD…
ICARUS-Breast-01
ESMO 2024
Her3-Dxd - new application area for ADCs
DestinyBreast-012
ESMO 2024
Outstanding efficacy of T-Dxd in CNS meastases
DESTINY-Breast 12,ICARUS-Breast-01, KEYNOTE-522
ESMO 2024
Optimization treatment with ADCs in endocrine therapy
ICARUS-Breast-01
ESMO 2024
HER3- DXd in the ICARUS Breast-01 study
Destiny-BREAST-12
ESMO 2024
Primary results of DB-12
ICARUS-Breast-01
ESMO 2024
Impression d'étude dans le cancer du sein métastatique…
ICARUS-Breast-01
ESMO 2024
Impressione dello studio nel carcinoma mammario…
Destiny-BREAST-12
ESMO 2024
Risultati primari dello studio DB-12
DESTINY-Breast 12,ICARUS-Breast-01, KEYNOTE-522
ESMO 2024
Optimization treatment with ADCs in endocrine therapy
Poster Sheel Robb C.
ESMO 2024
Endocrine resistance to CDK4/6 inhibitors
Detect IVa
ESMO 2024
CTCs as surrogate markers for endocrine therapy
ESMO 2024
Screening for brain metastases – what do doctors and…
PRIMA
ESMO 2024
Niraparib in ovarian cancer without survival benefit
CheckMate 77T, NEOSTAR & CA209-159, CCTG BR.31
ESMO 2024
Overview on the perioperative treatment landscape
AEGEAN, DUART
ESMO 2024
The importance of markers for patient management
LAURA
ESMO 2024
Significant CNS protection by osimertinib
AEGEAN
ESMO 2024
Getting rid of it will save your life!
AEGEAN
ESMO 2024
ctDNA - a promising new biomarker in early lung cancer
AEGEAN, CheckMate 77T
ESMO 2024
Neoadjuvant vs. Perioperative
CCTG BR.31
ESMO 2024
Should we move away from adjuvant immunotherapy?
CCTG BR.31
ESMO 2024
Durvalumab did not meet primary endpoint in CCTG BR.31…
CCTG BR.31, CheckMate 77T, CheckMate 816, NADIM
ESMO 2024
Perioperative IO Therapy - adjuvant necessary?
CCTG BR.31
ESMO 2024
BR31: The first negative adjuvant study in resected…
CCTG BR.31
ESMO 2024
Negative adjuvant CPI trial
AEGEAN
ESMO 2024
Eliminarlo potrebbe salvarti la vita
CCTG BR.31
ESMO 2024
BR31: La première étude d’immunothérapie adjuvante…
CCTG BR.31
ESMO 2024
Should we move away from adjuvant immunotherapy?
CCTG BR.31
ESMO 2024
Durvalumab non ha raggiunto l'endpoint primario nello…
RELATIVITY-104, GALAXIES Lung-102, NVALT-30
ESMO 2024
New 1st line treatment opportunities in advanced stage…
ALKOVE-1, PHAROS, KRYSTAL-12
ESMO 2024
Update on genetic alterations - ALK / ROS / KRAS / BRAF
MARIPOSA, MARIPOSA-2
ESMO 2024
Pieces of evidence in the EGFR domain
MARIPOSA
ESMO 2024
Early mechanisms of resistance from MARIPOSA
MARIPOSA-2
ESMO 2024
Sustained OS at 2nd interim analysis in MARIPOSA-2
NVALT-30
ESMO 2024
NVALT: 1st attempt to reduce dose of pembrolizumab and…
MARIPOSA-2
ESMO 2024
Second interim analysis of MARIPOSA-2
PHAROS, IFCT-1904 ENCO-BRAF
ESMO 2024
1st line encorafenib + binimetinib: combination is very…
NVALT-30
ESMO 2024
Half of the dose - same activity: provocative findings…
GALAXIES Lung-102
ESMO 2024
Two sometimes may be better than one!
MARIPOSA
ESMO 2024
Patterns of resistance in MARIPOSA trial
ARROS-1
ESMO 2024
The next generation of ROS inhibitors
RELATIVITY-104
ESMO 2024
Adding anti-LAG-3 doesn't seem to being worth it
MARIPOSA-2, MARIPOSA
ESMO 2024
Survival Data with Amivantamab for EGFR Alteration
ALKOVE-1
ESMO 2024
NVL-655: a promising new ALK inhibitor
ALKOVE-1, ALKOVE-1
ESMO 2024
4th generation with ALK-alterations
MARIPOSA
ESMO 2024
MARIPOSA - lower rate of MET amplification and EGFR…
ESMO 2024
Bispecific antibodies better than ADCs?
NVALT-30
ESMO 2024
Optimizing the dose of immunotherapy
ALKOVE-1
ESMO 2024
The next generation of ALK inhibitors
LUMINOSITY
ESMO 2024
Quality of life with Telisotuzumab in LUMINOSITY
RELATIVITY-104
ESMO 2024
RELATIVITY-104: efficacy of anti immunotherapy
GALAXIES Lung-201
ESMO 2024
Promising signal for anti-TIGIT + anti-PD-1 with PD-L1…
ARROS-1
ESMO 2024
NVL-520 for ROS alteration - already best in class?
LUMINOSITY
ESMO 2024
Quality of life with Telisotuzumab in LUMINOSITY
MARIPOSA-2
ESMO 2024
Second interim analysis of MARIPOSA-2
MARIPOSA
ESMO 2024
Patterns of resistance in MARIPOSA trial
PHAROS, IFCT-1904 ENCO-BRAF
ESMO 2024
CBNPC muté BRAF en 1ère ligne : encorafenib +…
NVALT-30
ESMO 2024
Optimizing the dose of immunotherapy
RELATIVITY-104
ESMO 2024
Aggiungere l'anti-LAG-3 non sembra valerne la pena
GALAXIES Lung-102
ESMO 2024
2 a volte sono meglio di uno
NVALT-30
ESMO 2024
NVALT: Première tentative pour réduire la dose de…
RELATIVITY-104
ESMO 2024
RELATIVITY-104: efficacy of anti immunotherapy
ADRIATIC, ARTEMIS, PACIFIC
ESMO 2024
New data on SCLC and mesothelioma
ADRIATIC
ESMO 2024
Subset analysis from ADRIATIC
ADRIATIC
ESMO 2024
New standard of care in LS-SCLC
ADRIATIC
ESMO 2024
Neuer Behandlungsstandard beim LS-SCLC
ARTIMES
ESMO 2024
Is the radiologist redundant in mesothelioma RECIST…
ARTIMES
ESMO 2024
Response assessment in mesothelioma - can AI help?
ARTIMES
ESMO 2024
Is the radiologist redundant in mesothelioma RECIST…
ARANOTE
ESMO 2024
Doublet therapy in prostate cancer: Practice changing…
SPLASH, PEACE-3, PSMAfore
ESMO 2024
Practice changing- Big Revival - Or just a Splish?…
CONTACT-02
ESMO 2024
IO in mCRPC: Let's move on to the next substance?!
SPLASH
ESMO 2024
New PSMA-ligand
PEACE-1
ESMO 2024
Molecular analysis from PEACE-1
CONTACT-02
ESMO 2024
Immunotherapy for prostate cancer
UpFrontPSMA
ESMO 2024
Upfronts in personal
PEACE-3
ESMO 2024
We come in PEACE
ESMO 2024
New hormone therapy for mCRPC
RAPSON
ESMO 2024
Radium223 Prior to Docetaxel Improves Quality of Life…
PEACE-3
ESMO 2024
Radium and enzalutamide in mCRPC - final results
ARANOTE
ESMO 2024
Darolutamide in mHSPC
PATCH
ESMO 2024
Not a Patch on ADT?
SPLASH
ESMO 2024
Was it a splash or was it a splish?
CONTACT-02
ESMO 2024
Did CONTACT make any contact?
STAMPEDE
ESMO 2024
Metformin in mHSPC
SPLASH, UpFrontPSMA
ESMO 2024
LuPSMA moves UpFront
PEACE-3
ESMO 2024
Radium-223 an option again?
UpFrontPSMA
ESMO 2024
PSMA-radioligand - the first study of its kind
PEACE-3
ESMO 2024
Radium and enzalutamide in mCRPC - final results
UpFrontPSMA
ESMO 2024
PSMA-radioligand - the first study of its kind
PEACE-1
ESMO 2024
Molecular analysis from PEACE-1
SPLASH
ESMO 2024
New PSMA-ligand
TACITO
ESMO 2024
Microbiome transplantation in RCC – how to tailor this…
SUNNIFORECAST
ESMO 2024
Establishing ICI as standard of care in RCC
Litespark-005, NKT2152
ESMO 2024
Where is the right place for HIF inhibitors in advanced…
TiNivo-2
ESMO 2024
IO after IO – is there a role for sequential…
SUNNIFORECAST
ESMO 2024
Treating nccRCC - Nivo/Ipi as a new potential option
TiNivo-2
ESMO 2024
TKI monotherapy remains standard in 2ndL
TACITO
ESMO 2024
Stool transplantation is the shit
SUNNiFORECAST
ESMO 2024
New SOC for non-cc-RCC?
SUNRISE-4
ESMO 2024
Opening a new way of treatment in MIBC
TiNivo-2
ESMO 2024
mRCC ≥ 1L? News on intensification?
SUNNIFORECAST
ESMO 2024
IO therapy is standard for nccRCC
SUNNIFORECAST
ESMO 2024
Ipi-Nivo in nccRCC
TiNivo-2
ESMO 2024
The role of sequencing therapy in RCC
CheckMate9ER
ESMO 2024
Glycoproteins as Predictive Biomarkers for Nivolumab…
LITESPARK-005
ESMO 2024
HIF-2a inhibitors are on their way
TiNivo-2
ESMO 2024
Sequencing checkpoint inhibitors - the story is over
TACITO
ESMO 2024
FMT in a novel setting
SUNNIFORECAST
ESMO 2024
My view on SUNNIFORECAST
TACITO
ESMO 2024
CPI - modification / prediction - fact or fantasy?
SUNNIFORECAST
ESMO 2024
Immunotherapy for nccRCC
SUNNIFORECAST
ESMO 2024
SUNNIFORECAST - rain or shine?
LITESPARK-005
ESMO 2024
Updated survival results
SUNNIFORECAST
ESMO 2024
Tratamiento del nccRCC - Nivo/Ipi como nueva opción…
TiNivo-2
ESMO 2024
Sequencing checkpoint inhibitors - the story is over
SUNRISE-4
ESMO 2024
Se abre una nueva vía de tratamiento en el cáncer de…
TOMBOLA, VOLGA, EV302
ESMO 2024
Biomarkers in Bladder cancer - the road to…
NIAGARA, AMBASSADOR
ESMO 2024
Chemo + IO in the perioperative setting - new standard…
SunRISe-4, SunRISe-1
ESMO 2024
Encouraging data - but we need more data!
SUNrise-1
ESMO 2024
Pretzel therapy for superficial UC
SUNrise-1
ESMO 2024
Is intravesical therapy as easy as baking a pretzel?
RC48G001
ESMO 2024
mUC - new ADC's?
NIAGARA, AMBASSADOR, TOMBOLA
ESMO 2024
Practice changing new data in Bladder cancer at ESMO24
CheckMate901
ESMO 2024
Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality…
EV-302, VOLGA, TOMBOLA
ESMO 2024
New data on ADCs in bladder cancer
NIAGARA
ESMO 2024
NIAGARA sets new standard
NIAGARA
ESMO 2024
New standard: perioperative MIBC-NIAGARA
EV-302
ESMO 2024
EV + Pembro is broadly effective
VOLGA
ESMO 2024
Value of ctDNA
SunRISe-4
ESMO 2024
A new way to give chemo for patients who are ineligible…
SunRISe-4
ESMO 2024
TAR200 intravesical +/- Cetrelimab in HR (N)MIBC
EV-302, VOLGA, TOMBOLA
ESMO 2024
Nuevos datos sobre las ADC en el cáncer de vejiga
NIAGARA, AMBASSADOR, TOMBOLA
ESMO 2024
Practice changing new data in Bladder cancer at ESMO24
SunRISe-4
ESMO 2024
A new way to give chemo for patients who are ineligible…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!